Meeting
2022 ASCO Annual Meeting
Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.
Authors
Timothy Lin
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
Timothy Lin , Alex Koong , Christine Lin , Joseph Abi Jaoude , Roshal Patel , Ramez Kouzy , Molly Blue El Alam , Sonal S. Noticewala , Ryan Sun , Clifton Dave Fuller , Charles R. Thomas Jr., Zachary McCaw , Ethan B. Ludmir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Clinical Research Design
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1561)
DOI
10.1200/JCO.2022.40.16_suppl.1561
Abstract #
1561
Poster Bd #
153
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).
First Author: Kynan Feeney
Poster
2020 ASCO Virtual Scientific Program
Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.
First Author: Chun Loo Gan
Poster
2016 Gastrointestinal Cancers Symposium
Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial.
First Author: Masatoshi Kudo